The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72874
Title:
The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma.
Authors:
Rosa, Daniela D; Ton, Nhuan C; Clamp, Andrew R; Mullamitha, Saifee A; Lau, Sin C; Clayton, Richard D; Kitchener, Henry C; Shanks, Jonathan H; McVey, Rhona J; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
AIMS: Ovarian cancer has a very poor prognosis, with 5-year survival rates of 5-20% for advanced-stage disease. This work was designed to verify whether the neoadjuvant approach had an effect on survival in patients with advanced-stage ovarian cancer. MATERIALS AND METHODS: Patients with stage III or IV disease who received neoadjuvant platinum-based chemotherapy (group 1) were compared with a group of conventionally treated patients (group 2). RESULTS: Most of the patients in group 1 (76%) had partial tumoral responses after chemotherapy. Patients from group 1 (n = 42) had a median survival that was not different from that in patients from group 2 (n = 348). Patients who received platinum-based chemotherapy with taxanes had the same survival of patients who received no taxanes. CONCLUSIONS: Our results showed similar responses and survival rates for patients with stage III or IV ovarian cancer treated with neoadjuvant platinum-based chemotherapy, when compared with patients who underwent primary suboptimal cytoreductive surgery. Our data therefore support the ongoing trials to determine the optimum timing of surgery for ovarian cancer.
Affiliation:
Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. dornellesrosa@hotmail.com
Citation:
The neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma. 2007, 19 (2):125-8 Clin Oncol
Journal:
Clinical Oncology
Issue Date:
Mar-2007
URI:
http://hdl.handle.net/10541/72874
PubMed ID:
17355108
Type:
Article
Language:
en
ISSN:
0936-6555
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorRosa, Daniela D-
dc.contributor.authorTon, Nhuan C-
dc.contributor.authorClamp, Andrew R-
dc.contributor.authorMullamitha, Saifee A-
dc.contributor.authorLau, Sin C-
dc.contributor.authorClayton, Richard D-
dc.contributor.authorKitchener, Henry C-
dc.contributor.authorShanks, Jonathan H-
dc.contributor.authorMcVey, Rhona J-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-07-07T16:10:29Z-
dc.date.available2009-07-07T16:10:29Z-
dc.date.issued2007-03-
dc.identifier.citationThe neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma. 2007, 19 (2):125-8 Clin Oncolen
dc.identifier.issn0936-6555-
dc.identifier.pmid17355108-
dc.identifier.urihttp://hdl.handle.net/10541/72874-
dc.description.abstractAIMS: Ovarian cancer has a very poor prognosis, with 5-year survival rates of 5-20% for advanced-stage disease. This work was designed to verify whether the neoadjuvant approach had an effect on survival in patients with advanced-stage ovarian cancer. MATERIALS AND METHODS: Patients with stage III or IV disease who received neoadjuvant platinum-based chemotherapy (group 1) were compared with a group of conventionally treated patients (group 2). RESULTS: Most of the patients in group 1 (76%) had partial tumoral responses after chemotherapy. Patients from group 1 (n = 42) had a median survival that was not different from that in patients from group 2 (n = 348). Patients who received platinum-based chemotherapy with taxanes had the same survival of patients who received no taxanes. CONCLUSIONS: Our results showed similar responses and survival rates for patients with stage III or IV ovarian cancer treated with neoadjuvant platinum-based chemotherapy, when compared with patients who underwent primary suboptimal cytoreductive surgery. Our data therefore support the ongoing trials to determine the optimum timing of surgery for ovarian cancer.en
dc.language.isoenen
dc.subjectGlandular and Epithelial Canceren
dc.subjectCancer Stagingen
dc.subjectOvarian Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoadjuvant Therapy-
dc.subject.meshNeoplasm Staging-
dc.subject.meshNeoplasms, Glandular and Epithelial-
dc.subject.meshOrganoplatinum Compounds-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshPrognosis-
dc.subject.meshRetrospective Studies-
dc.subject.meshSurvival Rate-
dc.subject.meshTaxoids-
dc.subject.meshTime Factors-
dc.subject.meshTreatment Outcome-
dc.titleThe neoadjuvant approach in the treatment of patients with advanced epithelial ovarian carcinoma.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. dornellesrosa@hotmail.comen
dc.identifier.journalClinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.